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ABSTRACT
Gliomas are extremely aggressive brain tumors with a
very poor prognosis. One of the more promising strat-
egies for the treatment of human gliomas is targeted
immunotherapy where antigens that are unique to the
tumors are exploited to generate vaccines. The
approach, however, is complicated by the fact that
human gliomas escape immune surveillance by creating
an immune suppressed microenvironment. In order to
oppose the glioma imposed immune suppression, mol-
ecules and pathways involved in immune cell matura-
tion, expansion, and migration are under intensive
clinical investigation as adjuvant therapy. Toll-like
receptors (TLRs) mediate many of these functions in
immune cell types, and TLR agonists, thus, are currently
primary candidate molecules to be used as important
adjuvants in a variety of cancers. In animal models for
glioma, TLR agonists have exhibited antitumor proper-
ties by facilitating antigen presentation and stimulating
innate and adaptive immunity. In clinical trials, several
TLR agonists have achieved survival beneﬁt, and many
more trials are recruiting or ongoing. However, a second
complicating factor is that TLRs are also expressed on
cancer cells where they can participate instead in a
variety of tumor promoting activities including cell
growth, proliferation, invasion, migration, and even stem
cell maintenance. TLR agonists can, therefore, possibly
play dual roles in tumor biology. Here, how TLRs and
TLR agonists function in glioma biology and in anti-gli-
oma therapies is summarized in an effort to provide a
current picture of the sophisticated relationship of gli-
oma with the immune system and the implications for
immunotherapy.
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INTRODUCTION
Gliomas are the most common neoplasms occurring in the
central nervous system (CNS), and are one of the most
aggressive types of human cancer. Histological classiﬁcation
of gliomas according to the World Health Organization con-
sists of grades I–IV (Louis et al., 2007), with grade I corre-
sponding to a benign tumor and grades II to IV increasing in
malignancy. Grade III and grade IV gliomas are considered
malignant and have a very poor prognosis. Glioblastoma
multiforme (GBM; grade IV), is the most aggressive form of
human glioma, and the mean survival of these patients
remains dismally at approximately 12 months despite
intensive and comprehensive therapies (Louis et al., 2007).
One of the more promising therapeutic strategies for the
treatment of human gliomas is immunotherapy. Elucidation
of the molecular basis for immune response is, therefore,
currently under rigorous analysis. Molecules fundamental to
eliciting an immune response in various immune cell types
are toll-like receptors (TLRs) and correspondingly, their
receptor agonists. TLRs are an evolutionarily conserved
family of pattern-recognition receptors with 10 functional
members (TLR 1–10) in human that are expressed on a
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variety of immune cell types. Toll-like receptor agonists are
pathogen-associated molecular patterns (PAMPs) that bind
to TLRs with speciﬁcity and in a typical scenario, initiate an
immune response. The complicating factor in glioma biology
is that the same TLRs are also found to be expressed on
glioma cells themselves. Further complicating the issue is
the fact that speciﬁc family members, such as TLR2, TLR4,
and TLR9, following detection of corresponding TLR ago-
nists, have a tumor promoting role in the biology of these
tumors.
Triggering TLRs to generate an immune response is
therefore a primary goal in immunotherapy for cancer in
general. The design of current strategies is to exploit anti-
gens uniquely presented by a tumor type so that the vaccine
will be speciﬁc, but to use TLR agonists as adjuvants to
potentially enhance the response. TLR agonists have been
well-described and furthermore have greater afﬁnities for
different TLRs so that they can be used to speciﬁcally probe
immune response in vivo. Currently, agonists, such as BCG
(TLR1, 2, 4, and 6), MPL (TLR4), poly(I:C) (TLR3), imiqui-
mod (TLR7), and CpG (TLR9), have been tested and
reported to initiate therapeutic effects to varying degrees in
clinical trials for colon cancer (Vermorken et al., 1999), uro-
thelial carcinoma (Sharma et al., 2008), non-small-cell lung
cancer (Vansteenkiste et al., 2007), lymphoma (Brody et al.,
2010), melanoma (Adams et al., 2008), and a number of
other cancers.
Many TLR agonists have been introduced into animal
models of glioma to investigate immunotherapies and their
underlying mechanisms. Since the expression of TLRs on
glioma cells has been associated with some tumor promot-
ing activities, it is important to summarize the major ﬁndings
concerning TLRs and TLR agonists in glioma models for a
more comprehensive view of this ﬁeld.
TLRS AND TLR AGONISTS
The Toll gene was initially described in Drosophila and found
to mediate dorsoventral embryonic development and innate
immune functions (Anderson et al., 1985). The human
homolog of Toll was subsequently cloned in 1997, and its role
in the human adaptive immune response was determined
(Medzhitov et al., 1997). Shortly thereafter, the ﬁrst toll-like
receptor, TLR4, was discovered (Poltorak et al., 1998). Cur-
rently, a total of 13 TLR genes have been identiﬁed in human
and mouse genomes; TLR1–10 are functional in human, and
TLR1–9 and TLR11–13 are functional in mouse.
Expression of the TLRs varies with immune cell type.
Among human antigen presenting cells (APCs), TLR7, 9,
and 10 are expressed on plasmacytoid dendritic cells
(pDCs), whereas all TLRs, with the exception of TLR9, are
expressed on myeloid derived DCs (mDCs). In human
adaptive immune system, TLR1, 2, 3, 4, 5, 7, and 9 (Caron
et al., 2005; Hornung et al., 2002; Zarember and Godowski,
2002) are expressed on T cells, and TLR5 and 8 (Crellin
et al., 2005; Kabelitz, 2007) are expressed on regulatory T
cells (Treg), a cell type critical to the maintenance of immune
homeostasis. Finally, activated and memory B cells express
signiﬁcant levels of TLR1, 6, 7, 9, and 10 but low levels of
TLR2 (Agrawal and Gupta, 2011; Bernasconi et al., 2003;
Hornung et al., 2002; Mansson et al., 2006).
TLR agonists are generally microbial molecules that
stimulate TLR receptors to initiate speciﬁc immunoactivity.
The most frequently studied of these agonists include lipo-
polysaccharides (LPS; TLR4 agonist), lipopeptides (TLR1,
TLR2, and TLR6 agonists), ﬂagellin (TLR5 agonist), single
stranded (TLR7 and TLR8 agonist) or double stranded (ds)
RNA (TLR3 agonist), and DNA containing the CpG motif
(TLR9 agonist). Recent studies indicate that endogenous
molecules released from stressed or dead cells such as heat
shock proteins (HSP; TLR2 and TLR4) and high mobility
group box 1 (HMGB1; TLR2 and TLR4) are also important
TLR agonists (Asea et al., 2002; Kepp et al., 2011).
When TLR agonists bind to their receptors, the bulk of
downstream signaling is generally executed through one of
two different pathways, myeloid differentiation factor 88
(MyD88)-dependent and MyD88-independent. The former
leads to early activation of NF-κB, MAPK, and transcription
of pro-inﬂammatory cytokines, chemokines, and cytosolic
enzymes, while the latter results in the activation of late
phase NF-κB and the interferon (IFN) regulatory factors
responsible for type I IFN expression (Akira and Takeda,
2004; O’Neill and Bowie, 2007).
EXPRESSION OF TLRS IN MICROGLIA
AND GLIOMA CELLS
For TLR agonist-based cancer immunotherapy, it is impor-
tant to carefully evaluate the role of TLR agonist in terms of
both systemic and regional effects in order to deliver the
most effective treatment with the least number of side
effects. Furthermore, while TLR expression on the immune
cells generally supports the therapeutic purpose, the
expression on cancer cells (Arunkumar et al., 2013; Cherﬁls-
Vicini et al., 2010; Huang et al., 2007; Kundu et al., 2008;
Nomi et al., 2010; Salaun et al., 2006) can corrupt the pro-
cess. TLRs are expressed on both the tumor cells and
microglia, a normal glial cell that makes up a major cellular
component of human glioma (da Fonseca and Badie, 2013).
The following section summarizes TLR expression patterns
and related biological responses in order to predict potential
regional effects elicited by TLR agonists in TLR agonist-
based glioma immunotherapy.
TLR expression on glioma cells
TLR2, TLR4, and TLR9 have been under investigation for
expression on glioma cells, and their contribution to tumor
development has been mostly described as tumor promoting.
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The expression levels of TLR2 are substantially elevated in
patient glioma biopsies and inversely correlate with patient
survival (Vinnakota et al., 2013). TLR2 expression has also
been detected in human glioblastoma U87 cells with touch-
down PCR (Haghparast et al., 2011) and subsequently
linked to tumor promotion. When cells were treated with the
TLR2 agonist peptidoglican (PGN), TLR2 initiated signaling
through the activation of NF-κB, which ultimately led to
increased cell growth (Echigo et al., 2012).
TLR4
TLR4 RNA and/or protein expression has been detected in
U118, U87, A172, and LN229 glioma cell lines (Gupta et al.,
2013; Sarrazy et al., 2011; Tewari et al., 2012). Protein
expression in primary biopsies from glioblastoma patients
has been found to be elevated relative to adjacent non-
neoplastic tissue by immunohistochemistry and Western blot
analysis (Tewari et al., 2012). In in vitro studies, different
tumor promoting effects were directly observed when cells
were exposed to the TLR4 agonist LPS. First, the prolifera-
tion of U118 and U87 and the invasion of U87 cells (Sarrazy
et al., 2011) were enhanced. The expression of the
metalloproteinase, MMP-9, which is essential for increased
invasion of the cells, was also elevated in U87 in response to
stimulation by LPS. Second, signaling through TLR4 was
found to be involved in mechanisms regulating cell survival,
migration and immune evasion, and resistance to TNF-α
treatment. TLR4 was either directly involved in these pro-
cesses or inﬂuenced their outcome.
Enhanced invasion mediated by TLR4 is potentially the
result of an intriguing mechanism that involves the binding of
extracellular heat shock protein 90 (HSP90) to TLR4 with
subsequent transactivation of epidermal growth factor
receptor (EGFR). HSP90 is a major protein produced in
response to tumor cell stress and is found at increased
extracellular levels in the tumor environment. In this mech-
anism, HSP90 binds to TLR4, which leads to activation of
EGFR and an increase in intracellular calcium levels nec-
essary to promote tumor cell migration (Thuringer et al.,
2011).
The release of speciﬁc cytokines that protect cells from
apoptosis or lead to the ability of tumor cells to altogether
evade immune detection may also be due to the expression
of TLR4 on glioma cells. The resistance of gliomas to
apoptosis, induced in one scenario by TNF-α, is possibly due
to the release of cytokines IL-6, IL-8, and MCP-1, in fact, in
response to TNF-α treatment (Tewari et al., 2009). IL-8 is
associated with hypoxia induced glioma progression (Brat
et al., 2005), and MCP-1 is responsible for the tumor pro-
moting activity of microglia (Platten et al., 2003). In tumor
cells, it is TLR4 that is activated by TNF-α, via TIR-domain-
containing adapter-inducing interferon-β (TRIF) dependent
pathway, forming a feed-forward loop with TNF-α, which
triggers the release of these cytokines (Tewari et al., 2012).
IL-1β is an additional cytokine secreted by glioma cells
subsequent to TNF-α treatment. This cytokine actually
induces TLR4 expression, via hypoxia inducible factor 1-α
(HIF-1α), which results in the elevation of HMGB1 in glioma
cells. The upregulation of TLR4 and HMGB1 is synergistic
and results in the increase of HLA-G, a non-classical HLA
class I antigen that participates in glioma immune evasion
(Gupta et al., 2013).
One potential way to bypass these particular challenges
due to the expression of TLR4 on glioma cells is through the
activation of the Fas pathway. Engagement of this pathway
generally leads to apoptosis in a variety of cancers (Shino-
hara et al., 2000), including glioma (Zhao et al., 2007).
Interestingly, when TLR4 and Fas were simultaneously
activated, the tumor promoting capabilities of TLR4 were
lost, as well as the increased expression of MMP-9, which
was necessary for the U87 cell invasion stimulated by LPS
alone. The molecular details of how these two molecules/
pathways functionally intersect requires further investigation,
however, to be of therapeutic value (Sarrazy et al., 2011).
TLR9
TLR9 is expressed on human cell lines U251, U87, and the
murine cell line C6. This receptor is also found in primary
human glioma biopsies and isolated human glioma stem-like
cells. Clinically, increased expression of TLR9 has been
associated with higher tumor grade and worse prognosis.
Functionally, studies have demonstrated that TLR9 mediates
the properties of enhanced invasion and proliferation. Stud-
ies have demonstrated that the TLR9 agonist, CpG dinu-
cleotide, enhances cell invasion in vitro through TLR9 (Wang
et al., 2010). In addition, there is a correlation between TLR9
and the metalloproteinases MMP2 and MMP9 in clinical
samples (Leng et al., 2012; Wang et al., 2010). Activated
TLR9 also promoted growth of glioma stem-like cells through
the activation of STAT3 signaling in vitro, which is a pathway
participating in numerous tumor promoting activities (Herr-
mann et al., 2014). In contrast, CpG dinucleotides also
function as a radio-sensitizer potentially through TLR9. CpG
raises nitrogen monoxide (NO) levels in CpG treated U87
cells through TLR9 mediated NF-κB signaling, thereby
potentiating the radiosensitivity of the cells in vitro (Li et al.,
2012).
How TLRs might be controlled by other events occurring
during tumor development is illustrated by the regulation of
TLR9 by insulin growth factor 1 (IGF1). IGF-1 is a well-
known growth factor associated with tumor growth. In gli-
oma cells, IGF-1 induced TLR9 through HIF-1α signaling,
mediated by Ras and calmodulin dependent kinase II
(CaMK II). Enhanced expression of TLR9 induced by IGF-1
resulted in the secretion of IL-1β, IL-6, IL-8, and the
elevation of CXCR-4, a receptor that plays an important
role in cell migration. CXCR-4 may thus underlie the
mechanism for TLR9 enhancement of the metastatic
potential of glioma cells (Sinha et al., 2011).
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In summary, TLR agonists bring potential risks to immu-
notherapies because these receptors can also initiate tumor
promoting biological processes when expressed by glioma
cells. For this reason, thorough studies of TLR expression in
glioma cells, the effect of different TLR agonists for the same
TLR or different TLRs on glioma cells in vitro, and the
underlying molecular mechanisms are critical for the proper
guidance and design of therapies.
TLRs and microglia
Microglia is a type of tissue resident macrophage of myeloid
origin and perform brain speciﬁc immune surveillance.
These glial cells heavily inﬁltrate gliomas, and can constitute
up to 30% of the inﬁltrating normal cell population (the
stroma). The local density of microglia can be as great as 20
times higher in glioma than normal brain tissue (Hussain
et al., 2006b). TLR2, 3, 4, and 9 are highly expressed on
both human microglia in the normal brain parenchyma and
tumor-inﬁltrating microglia. However, despite similar levels in
TLR expression (Hussain et al., 2006b; Meng et al., 2008),
the function of the inﬁltrating microglia is highly inﬂuenced by
the tumor microenvironment.
TLRs play an important role in the regulation of microglial
activity during gliomagenesis. For example, membrane type
1 matrix metalloproteinase (MT1-MMP) is a molecule in
microglia that controls response to certain growth factors in
neovascularization, and engagement of this molecule is one
way that microglia contributes positively to glioma growth.
Expression of TLR2 in microglia is necessary for the acti-
vation of MT1-MMP by neighboring glioma cells, and the
process is MyD88 dependent (Vinnakota et al., 2013). Based
on these results and the fact that the molecule is highly
expressed in human gliomas, TLR2 was examined as a
potential biomarker, and its expression was found to be
inversely correlated to patient survival (Vinnakota et al.,
2013).
Microglia isolated from patient biopsies, however do
retain their antitumor properties. Poly(I:C) stimulation polar-
ized isolated microglia in vitro toward an antitumor M1-like
proﬁle which resulted in increased microglial production of
inﬂammatory cytokines TNF-α and IL-12 (Kees et al., 2012).
These supernatants induced apoptosis and inhibited migra-
tion of glioma cells. The experiment was also performed in
the presence of glioma cells to determine how the tumor
microenvironment inﬂuenced microglial function. When co-
cultured with glioma spheroids, poly(I:C) stimulated microglia
were impaired with respect to their antitumor properties
(Kees et al., 2012). Similar effects were observed when
microglia was stimulated with a second TLR agonist, LPS.
LPS also stimulated microglia to produce TNF-α in vitro, but
glioma cells both through paracrine and direct cell-contact
mechanisms, inhibited this effect. The study also revealed
that the glioma cells induced microglia to secrete the anti-
inﬂammatory cytokine IL-10 and to up-regulate STAT3
signaling activity, two activities that are tumor promoting
(Kostianovsky et al., 2008).
TLRs mediate both tumor promoting and tumor inhibiting
functions of microglia. Glioma cells skillfully usurp these glial
cells for their growth promoting properties, and yet, microglia
remains fundamentally unaltered with regard to their tumor
inhibiting functions. Thus, microglia and TLR signaling are
tools that may be manipulated for therapeutic purposes,
particularly in light of the fact that these cells constitute a
considerable fraction of human gliomas. Although engage-
ment of TLR3 and TLR4 pathways alone, for example, may
not be sufﬁcient to eradicate tumors, targeting these recep-
tors could be considered as a supplement to therapy until
mechanisms of glioma cell suppression on microglia are
more clearly understood.
TLRS AND ANTI-GLIOMA IMMUNITY
Local immune suppression is one part of the challenges that
face immunotherapy; immune suppression is a systemic
manifestation of cancer as well. Research efforts to boost
the immune response in cancer patients are therefore also
focused on more fundamental failures of the immune system
in cancers. Here, TLR agonists in glioma immunotherapies
have also been promising as tools to activate APCs and
effector T cells, and in general to reverse glioma induced
suppression of maturation of these cell types. The following
content reviews recent advances that describe how TLRs
and TLR agonists contribute to the development of anti-gli-
oma immunity.
TLRs and glioma antigen presentation
DCs in the brain develop from pre-DCs located in meninges
and choroid plexus (Anandasabapathy et al., 2011). Some
investigators believe that DCs actually carry antigens from
the CNS and migrate deep into the cervical lymph nodes
(CLN) in order to activate the maturation of residing naive T
cells (Karman et al., 2004). However, whether DC cells do
migrate out of the CNS and how they do so, still remains
controversial (Weller et al., 2009). Generally, DCs are
thought to be the APCs fundamental to the development of
effective anti-glioma immunity. Therefore, the role of TLR
agonists in the maturation of DCs and the enhancement of
their capacity for migration and antigen presentation is cur-
rently under rigorous investigation.
TLRs and DC activation
In contrast to its role in glioma-derived microglia, TLR2
expression on DCs is of potential beneﬁt to immunogenic
glioma cell lysis. Stimulation of the receptor by a corre-
sponding endogenous or synthetic agonist has been shown
to effectively initiate activation of DCs through NF-κB sig-
naling. A novel method of locally producing a desired
endogenous agonist was through gancyclovir mediated cell
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death of glioma cells expressing thymidine kinase from
adenovirus. The release of HMGBI, a TLR2 agonist, from the
dead glioma cells stimulated TLR2 (Foldi, 1999), and in
combination with the local expression of the DC growth
factor Fms-like tyrosine kinase 3 ligand (Flt3L) (Maraskovsky
et al., 1996; Pulendran et al., 1997), led to expansion and
activation of DCs resulting in the production of inﬂammatory
cytokines TNF-α and IL-6 (Curtin et al., 2009) necessary to
initiate an effective anti-glioma immune response (Ali et al.,
2004). Weighing the balance in the dual character of TLR2
therefore appears to be an important consideration in the
development of anti-glioma immunotherapies.
Systemic introduction of synthetic TLR agonists poly(I:C),
imiquimod, and CpG also facilitated glioma antigen presen-
tation. In an intracranial glioma model, imiquimod increased
the number of DCs in the blood and CLN, and led to the
doubling of the number of DCs in the brain (Xiong and
Ohlfest, 2011). CpG was reported to activate and mature
DCs as well (Krieg, 2006). Furthermore, a study in the
murine model indicated that CpG achieved higher efﬁcacy in
the maturation of DCs when it was administered subcuta-
neously with tumor lysates. The combination exerted a
synergistic effect in increasing the number of activated DCs
in the cervical draining lymph nodes and eradicated intra-
cerebral GL261 glioma cells in the mice (Wu et al., 2007). In
a clinical trial, a DC vaccine with imiquimod or poly(I:C) as an
adjuvant, boosted serum TNF-α and IL-6 levels in glioblas-
toma patients (Prins et al., 2011).
TLRs and glioma induced DC suppression
The greatest challenge to immunotherapy is to overcome the
local immunosuppressivemicroenvironment. TGF-β secreted
by tumor cells is one of the most important and extensively
studied factors contributing to glioma microenvironment
immune suppression (Kjellman et al., 2000). TGF-β enables
the tumor to efﬁciently evade immune surveillance by potently
suppressing the maturation and function of DCs, which leads
to a deﬁciency in antigen presentation and immune response
(Grauer et al., 2007). Any effective immunotherapy, thus,must
enable DCs to both mature and produce IL-12 in order to
produce cytotoxic/mature T cells. TLR7 agonists that directly
target DCs have been used in an attempt to reverse this
immune suppression. R848 (TLR7/TLR8 agonist) in a cocktail
with TNF-α, IL-1β, and IFN-γ induced DC maturation and the
production of IL-12 (Grauer et al., 2007).
Factors in addition to TGF-β are also likely to contribute
to the immune suppressive milieu in glioma, and through
novel mechanisms. In one study, DCs isolated from fresh
glioma biopsies were found to be refractory even to TLR
agonist stimulation in vitro (Hussain et al., 2006a). A sep-
arate study identiﬁed lactate as an additional molecule that
suppresses the immune response, and thus is also
responsible for the resistance of DCs to TLR agonist
stimulation (Chirasani et al., 2013). Lactate is abundant in
glioma and most aggressively proliferating tumors (Walenta
and Mueller-Klieser, 2004). Lactate decreased IL-12 pro-
duction from mouse intracranial glioma derived DCs stim-
ulated by R848, and even altered the function of the
agonist, which resulted in the activation of STAT-3 signaling
in DCs and subsequent suppression of their maturation.
Small molecule inhibition of lactate enabled the TLR7/8
agonist R848 to stimulate secretion of IL-12 by DC in the
glioma environment thereby alleviating immune suppres-
sion (Chirasani et al., 2013).
TLRs and anti-glioma immune response
After successful antigen presentation by DCs, effector Tcells
are activated to kill glioma cells. Their levels are subse-
quently redistributed in the tumor, brain, CLNs, and blood.
TLR agonists delivered either systemically or locally, with or
without tumor lysate/antigens, have achieved observable
changes in the levels of these immune cell types in a variety
of preclinical murine glioma models, that resulted in either
eradication of the tumor or suppression of tumor growth. The
main players involved in anti-glioma TLR immunotherapy are
CD8+ T cells, which are assisted by CD4+ T cells. In certain
studies however, the effector cells are not limited to the
adaptive immunity. Members of the innate immune system,
such as NK cells, also make important contributions
depending on the agonist used and the therapeutic approach
chosen (Alizadeh et al., 2010; Zhao et al., 2011). Cytokine
changes can be associated with tumor suppression and
under certain conditions, present independent factors that
must be taken into consideration. Positive immunothera-
peutic roles elicited through a variety of mechanisms have
involved TLR2, TLR3, TLR4, TLR7, and TLR9 in these cell
types.
TLR2
Bacterial lipoprotein (TLR2 agonist) administered with anti-
gen-speciﬁc T cells achieved long-term survival and immune
memory in the murine GL261 glioma model (Zhang et al.,
2014). In this study, a TLR1/TLR2 agonist enhanced the
survival and function of administered T cells and altered the
glioma microenvironment by simultaneously elevating the
number of CD8+ positive T cells and down-regulating the
number of immunosuppressive myeloid-derived suppressor
cells (MDSCs). This effect was TLR2 dependent. In other
experiments, endogenous TLR2 agonist HMGB1, released
from glioma cells by targeted treatment with gancyclovir,
activated DCs and facilitated therapy (Curtin et al., 2009).
Under this treatment strategy, nearly half of the mice bearing
intracranial GL261 gliomas achieved long-term survival and
anti-glioma immunological memory in a TLR2 dependent
manner. The therapy stimulated the clonal expansion of gli-
oma antigen speciﬁc T cells in tumor bearing mice, with a
signiﬁcantly higher proportion of T cell precursors releasing
IFNγ in response to glioma antigen.
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In the murine CNS model, poly(I: C) enhanced induction,
expansion, and CNS homing of antigen speciﬁc T cells.
CD8+ positive Tcells in CLNs displayed higher expression of
alpha4 beta1 integrin (very late activation antigen 4, VLA4),
a molecule that favors CNS tropism (Calzascia et al., 2005).
Poly(I:C) facilitated tumor antigen speciﬁc T cell homing via
VLA4 up-regulation. In addition, poly(I:C) stimulated T cells
to produce more IFN-γ in the intracranial glioma microenvi-
ronment (Zhu et al., 2007).
TLR4
Two TLR4 agonists, LPS and Spirulina complex polysaccha-
ride, have demonstrated efﬁcacy in mice with subcutaneous
implantation of DBT and RSV-M gliomas, respectively (Chic-
oine et al., 2007; Kawanishi et al., 2013). TLR4 signaling was
activated and a variety of immune cell types, includingCD4+ T,
CD8+ T, NK cells, and macrophages, were exploited in tumor
suppression. One major difference between the mechanisms
of glioma suppression utilized by LPS and Spirulina complex
polysaccharide in glioma suppression is that LPS elevates
IL-17 in mouse serum while Spirulina complex polysaccharid
downregulates thecytokine. IL-17 is apleiotropic cytokinewith
pro- or anti-tumor potential depending on the tumor model. In
the murine gliomamodel, IL-17 was shown to promote glioma
growth (Chicoine et al., 2007). Moreover, Spirulina complex
polysaccharide was less toxic. These particular studies on
TLR4 agonists also highlight the importance in general of
optimizing their utility, such as lowering toxicity while main-
taining antitumor activity, in a clinical setting.
TLR7
Topical administration of the TLR7 agonist imiquimod has
been approved by the FDA in the treatment of skin cancers
and genital warts. In one of the more unusual treatment
approaches, topical administration of imiquimod (shoulder
and ﬂank) was also employed in amouse gliomamodel and in
fact eradicated the intracranial tumor (Xiong and Ohlfest,
2011). Topical administration in the mice depleted CD4+ Tand
CD8+ T cells in the peripheral blood circulation, redistributed
them in mouse CLNs and brain, and reversed tumor immune
suppression by signiﬁcantly reducing the absolute number of
Tregs in the tumor microenvironment. These responses all
together led to intracranial tumor inhibition. The topical
administration of imiquimod also released/activated brain
inﬁltrating lymphocytes from the refractory state induced by
the intracranial tumor (Xiong and Ohlfest, 2011). Moreover,
antitumor immune memory developed in mice subcutane-
ously injected with imiquimod (Stathopoulos et al., 2012).
TLR9
The TLR9 agonist CpG has been shown to eradicate murine
intracranial glioma when subcutaneously administered with
tumor lysate and effector T cells (Wu et al., 2007). Further
investigation into local administration of CpG analyzed the
change in the balance between effector Tcells and regulatory
T cells at the tumor site. The ratio of CD8+ T effector cells to
CD4+FoxP3+Tregs in the tumor environmentwas shown to be
increased. In CLNs, antigen-speciﬁc activation of CD4+ and
CD8+ T cells was observed with CpG administration (Grauer
et al., 2007).
Side effects, such as a transient worsening of baseline
neurological symptoms resulting from brain edema (Cal-
zascia et al., 2005; da Fonseca and Badie, 2013), occurred
in the CpG clinical trial. One clinical study attempted to avoid
the severe neural inﬂammation caused by the single high
dose injection by applying CpG through multiple injections at
a lower dose. In this study, NK cells were found to be
increased and were higher than CD8+ T cells in the tumor.
Depletion of NK cells with antibody completely abrogated the
antitumor effect, while only a minor reduction in efﬁcacy was
observed after CD8+ T cell depletion (Alizadeh et al., 2010).
Another important ﬁnding of this study was the signiﬁcant
elevation of MDSCs, but not Tregs, in the brain, blood, and
spleens in response to the single high dose injection of CpG-
ODN. This ﬁnding supports the administration of multiple low
dose injections of CpG rather than a single high dose
injection (Alizadeh et al., 2010). Other methods of drug
delivery, carbon nanotube application, appeared to also
enhance the efﬁcacy of CpG, including a survival beneﬁt.
The study also conﬁrmed the roles of CD8+ T cells and NK
cells in the anti-glioma immune response (Zhao et al., 2011).
Based on the current literature, TLR3 and TLR7 agonists
may be generally categorized as “safe” agonists to use in
glioma therapy, as response is largely tumor inhibition in the
absence of tumor promotion. However, evidence of TLR3
and TLR7 tumor-promotion has been reported for other
cancers such as in lung, pancreas, and liver (Chatterjee
et al., 2014; Eigenbrod and Dalpke, 2013; Eiro et al., 2014;
Zhan et al., 2014). Further investigation is, therefore, nec-
essary to conﬁrm these observations. In the case of TLR4
and TLR9 agonists, the recommendation is to remain cau-
tious when considering their roles in anti-glioma therapies.
Results already demonstrate that in vitro and in vivo studies
do not completely overlap. One important line of investiga-
tion for the future is to perform in vivo studies of human
glioma cell lines in humanized mouse models in order to fully
understand the nature of the anti-tumor and pro-tumor
effects of TLR4 and TLR9 agonists.
CLINICAL TRIALS BASED ON TLR AGONIST
THERAPY
Biological rationale for immunotherapy in the central
nervous system
The human central nervous system was once regarded as
immunologically privileged. Several factors that constitute an
effective immune system were thought to be absent or
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insufﬁcient in the CNS. They included the mode of entry for
immune cells which was thought to be blocked by the blood
brain barrier (BBB), the lymphatic vascular system, and
major histocompatibility complex (MHC) and local antigen
presenting cells (Muldoon et al., 2013). Current under-
standing has replaced the previous concept of the CNS
immune system, as a result of the discovery of some CNS
speciﬁc mechanisms for eliciting immune response. First,
the BBB is compromised in pathological conditions such as
inﬂammation and tumor development, and under pharma-
cological modiﬁcation with BBB speciﬁc disruptive agents
(Bartus et al., 1996; Boskovitz et al., 2004; Elliott et al., 1996;
Stamatovic et al., 2008; Wang and Casley-Smith, 1989;
Wolburg et al., 2005). Any one of these conditions thus
theoretially provides the opportunity for entry of both immune
cells and therapeutic monoclonal antibodies. Second,
instead of lymphatic drainage in the traditional sense, CNS
immunological contact with its draining CLN is established
through the perineural lymphatic pathway (Foldi, 1999) and
the prelymphatic-lymphatic system (Wang and Casley-Smith,
1989). Third, CNS residing microglia, with a poor antigen
presentation ability in the resting state, could be stimulated
by an underlying pathology in the CNS to interact with Tcells
and become effective APCs (Yang et al., 2010). In addition,
macrophages and especially DCs, though limited in the brain
parenchyma, are abundant in choroid plexus epithelium and
serve as strong APCs under certain biological and patho-
logical conditions (Hussain and Heimberger, 2005; Serot
et al., 1997). Finally, the CNS has its own immune surveil-
lance system. The immune cells enter the cerebrospinal ﬂuid
(CSF) at the position in the choroid plexus where CSF is
produced, and CSF circulation establishes immune surveil-
lance (Provencio et al., 2005).
Current status of clinical trials based on TLR agonist
therapy
An important aspect of the utilization of TLRs in glioma clinical
trials is the application of TLR agonists as single agents to
suppress the tumor. A number of trials have been designed
Table 1. Clinical trials in glioma immunotherapy with TLR agonists
Diagnosis TLR target Agent Phase Status Trial
GBM TLR3 PolyICLC/ APVAC1 vaccine 1 Not recruiting NCT02149225
AIII, GBM TLR3 PolyICLC/IMA950 1/2 Recruiting NCT01920191
Recurrent Ped LGG TLR3 PolyICLC 2 Recruiting NCT01188096
Recurrent AII, OII, OAII TLR3 PolyICLC/glioma peptide 0 Not
recruiting
NCT00874861
Recurrent GBM, AIII, OIII, OAIII TLR3 PolyICLC/DC vaccine 1/2 Not
recruiting
NCT00766753
AIII, OAIII, GBM TLR3/TLR7 PolyICLC/Resiquimod/DC
vaccine
2 Recruiting NCT01204684
Ped pontine glioma, ped HGG,
recurrent ped LGG, recurrent
ped HGG
TLR3 PolyICLC/ glioma peptide – Recruiting NCT01130077
GBM/post operative TLR3 PolyICLC/radiation 2 Completed NCT00052715
AIII, OIII, OAIII TLR3 PolyICLC 2 Unknown NCT00058123
GBM/post operative TLR3 PolyICLC/Temozolomide/
radiation
2 Completed NCT00262730
High risk AII, OAII TLR7 Imiquimod/Tumor lysate
vaccine
0 Recruiting NCT01678352
Recurrent Ped ependymoma TLR7 Imiquimod/glioma peptide 2 Recruiting NCT01795313
Recurrent GBM, AIII TLR7 Imiquimod/DC vaccine/
Tumor lysate
2 Recruiting NCT01808820






(tumor stem cell loaded)
1 Completed NCT01171469
PedGBM, HGG TLR7 Imiquimod/DC vaccine/
Tumor lysate
1 Recruiting NCT01902771
GBM TLR9 CpG-ODN 2 Completed NCT00190424
A astrocytoma, O oligodendroglioma, OA oligoastrocytoma, GBM glioblastoma multiforme, ped pediatric, LGG low grade glioma, HGG high
grade glioma.
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based on this strategy, and some have supplemented TLR
treatment with chemo- and radio-therapies. To date, three
clinical trials have been completed with published results.
One CpG phase II clinical trial has been completed for
patientswith recurrentGBM.A total of 34patientswith recurrent
GBM were enrolled; CpG was administered intracerebrally to
31/34 patients. Overall, the therapy was well tolerated. The
6-month progression free-survival (19%) was increased com-
pared to the control group (3%). One partial response (−78%)
and 3 minor responses (−33%, −26%, and −25%) were
observed. Adverse events associated with therapy included
lymphopenia, mild fever, seizures, and worsening of baseline
neurological symptoms (Carpentier et al., 2010).
Two Phase II polyICLC (a chemically and biologically stable
formofpoly(I:C)) trialshavebeencompleted. Inoneclinical trial,
which evaluated the therapeutic efﬁcacy of polyICLC in com-
bination with irradiation for newly diagnosed GBM patients,
muscle injection of polyICLC was administered to 30 patients.
The treatment achieved a survival beneﬁt compared to histor-
ical studies using irradiation without chemotherapy, but no
survival beneﬁt compared to irradiation with adjuvant nitro-
sourea or non-temozolomide chemotherapy. Toxicity was
generally minor, but could be accompanied by fatigue, leuco-
penia, lymphocytopenia, and pain at the site of injection (Bu-
towski et al., 2009). PolyICLC was further tested as adjuvant
therapy on postoperative glioblastoma patients in combination
with the current standard for treatment, irradiation and tem-
ozolomide (TMZ). At theendpoint of the trial, the overall survival
at 12 and 18 months was greater than in the previous EORTC
phase III trial in which patients were treated with irradiation and
TMZ (Rosenfeld et al., 2010; Stupp et al., 2005).
In many other clinical trials, TLR agonists are designed to
be administered with other glioma vaccines as adjuvant.
Most of these clinical trials focus on tumor antigens and DCs
(Jackson et al., 2013). Several antigens or glioma speciﬁc
molecules have been characterized and utilized in glioma
vaccines, including epidermal growth factor receptor variant
III (EGFRvIII), IL-13 receptor α2, IL-4 receptor, and heat
shock protein (HSP) gp96 (Eguchi et al., 2006; Graner et al.,
2007; Kawakami et al., 2000; Li et al., 2010). However,
instead of single antigens, many more designs utilize a
mixture of antigens, namely tumor lysate that contains most
of the glioma antigens that have been discovered. Further-
more, regarding DCs in vaccines, the most important APCs
are artiﬁcially derived in an in vitro environment to enhance
contact between the cells and the antigens. TLR agonists
are thereby designed into the procedure to augment the
therapeutic effect.
Table 1 lists all current clinical trials for TLR agonists in
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Figure 1. TLR agonists stimulate both anti- and pro-glioma processes. Biological activities initiated through TLR pathways are
dependent on the receptor stimulated, the cell type, and the microenvironment. In the anti-glioma process, TLR agonists encourage
the development of an immune environment by directly stimulating DC and T cell maturation. In addition, TLR activation in these cell
types opposes the immune suppressive environment by favoring CNS tropism. Migration elevates the numbers of these cells in the
CNS tumor and CLN and initiates anti-glioma immunity. TLR agonists also induce microglia isolated from primary gliomas to produce
inﬂammatory cytokines and acquire anti-glioma activity. In contrast, activation of TLR2, TLR4, and TLR9 in microglia facilitates pro-
glioma activities, such as tumor cell growth, invasion, and migration.
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patient recruiting stage. The trials are mainly focused on the
therapeutic utility of agonists for TLR3, TLR7, and TLR9. The
targets of the immunotherapy include primary and recurrent
gliomas of different grades and pathology from pediatric as
well as adult patients. Identiﬁer numbers for the clinical trial are
listed in the table, and for more detailed information, please
refer to the government website: http://www.clinicaltrials.gov.
Finally, new developments emerging from studies on TLR
agonists in many other tumor models may also be relevant to
immunotherapy for glioma patients. Firstly, tumor antigens
for vaccines are derived from lysates of cancer stem cells in
order to more aggressively generate an anti-tumor response.
In a murine model of triple negative breast cancer, CpG was
administered as an adjuvant in a vaccine based on a breast
cancer stem cell lysate, which achieved tumor regression
and a survival beneﬁt (Liu et al., 2013). Secondly, combi-
nation therapies of different TLR agonists have been repor-
ted to exert synergistic stimulatory effects upon anti-tumor
immune response. Co-delivery of 3 M-052 (TLR7, TLR8
agonist) and CpG ODN via intratumoral injection has led to
complete rejection of large tumors (colon cancer and mela-
noma) in murine models, while delivery of 3 M-052 or CpG
ODN alone only reduced the tumor growth rate (Zhao et al.,
2014). Thirdly, TLR agonists have been combined with
therapeutic agents targeting certain immunosuppressive
factors. BCG administered with IL-10 receptor 1 monoclonal
antibody resulted in enhanced anti-tumor immunity in a
murine model of metastatic bladder cancer, which had been
initially resistant to BCG treatment alone (Newton et al.,
2014). Similar ﬁndings were reported from a study on a
murine lymphoma model treated with CpG and IL-10 siRNA
(Pradhan et al., 2014). Lastly, efforts are being made to
enhance anti-tumor response with improvements in the
delivery system for TLR agonists, such as with cationic lip-
osomes. Cationic liposomes have been found to potentiate
anti-tumor immune responses induced by poly(I:C) in murine
melanoma models (Hansen et al., 2012), and to engage
TLR4 on tumor associated macrophages that also resulted
in anti-tumor immune response (Huang et al., 2013). A more
novel approach for delivery exploited a type of nanogel
which was loaded with CpG ODN or polyICLC and peptide
antigen. This combination was reported to be capable of
speciﬁcally delivering the vaccines to the draining lymph
nodes and preferentially activating the medullary macro-
phages (Muraoka et al., 2014), which resulted in effective
cross-priming of vaccine speciﬁc effector T cells and anti-
tumor activities in murine colon cancer and sarcoma models.
CONCLUSIONS
Immunotherapy designed against human gliomas is funda-
mentally challenged by the sophisticated interactions
between gliomas and their immunological environments. In
addition, TLRs are distributed widely among cell types and
can elicit completely different responses depending on the
cell and the environment (Fig. 1). Most studies fractionate
these differences by focusing on one TLR and one tumor cell
type as the target for study. However, the nature of the
widespread expression and the combined effect of TLRs and
TLR agonists underlie the necessity for a more compre-
hensive understanding of their function in glioma therapies.
Results from many biological disciplines have contributed to
our current molecular and clinical understanding, but infor-
mation is still lacking, and many questions await answers.
What is the general distribution of glioma TLR expression on
an epidemiological scale? What are the real clinical effects of
TLR agonists on glioma patients? How do we select and
administer TLR agonists and maximize their anti-tumor effect
while minimizing their pro-tumor potential? Is it possible or
necessary to adopt a combination(s) of different TLRs and
agonists in glioma treatment? Answering these questions
requires further molecular and clinical investigation, which
will undoubtedly lead to new, perhaps groundbreaking
insights for the clinical management of human glioma.
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